Statistical Analysis Plan

Study Code: MedBridge

Study Title: Medication Reviews Bridging Healthcare (MedBridge): a cluster-randomised crossover trial

Based on protocol version and date: 2019-02-20 (previous version: 17-02-22)

Biostatistician: Nermin Hadziosmanovic

Clinical Project Leader: Ulrika Gillespie

Project Coordinator: Thomas Kempen

Principal investigator: Uppsala University Hospital (Akademiska sjukhuset), Sweden

Trial registry: ClinicalTrials.gov: NCT02999412

Reviewed and approved by Biostatistician (UCR);

Name: Signature: Date:

Approved by Principal Investigator’s Representative;

Name: Signature: Date:

SAP version: Final
Table of Contents

1. Introduction .......................................................... 3
2. Abbreviations ............................................................ 3
3. Study Objectives and Endpoints ...................................... 4
   3.1. Objectives .......................................................... 4
       3.1.1. Primary Objective ........................................ 4
   3.2. Endpoints .......................................................... 4
       3.2.1. Primary Endpoint .......................................... 4
       3.2.2. Secondary Endpoints ..................................... 4
4. Study design ............................................................. 5
5. Definition of Analysis Populations .................................... 6
6. Description of statistical analysis ..................................... 6
   6.1. General ............................................................ 6
   6.2. Patient and Cluster Characteristics .............................. 6
   6.3. Primary analyses ................................................ 7
   6.4. Secondary analyses .............................................. 7
   6.5. Subgroup analyses .............................................. 8
   6.6. Overdispersion .................................................. 9
   6.7. Handling of Missing Data ....................................... 9
7. Determination of sample size .......................................... 9
8. Changes in the Planned Analysis ..................................... 10
9. Description of Derived Variables .................................... 11
10. Description of Output ................................................ 13
11. Statistical software .................................................. 13
12. References ............................................................ 13
1. Introduction

The aim of this statistical analysis plan (SAP) is to describe details of planned statistical analyses and presentation of the study data described to be performed by the UCR (Uppsala Clinical Research Center) Statistics Section. UCR will perform all analyses of primary and secondary outcome measures and pre-specified subgroups, except for analysis of costs of hospital-based care. Data on costs of hospital-based care will be available by 2020 and may be part of a separate agreement between the principal investigator and UCR. The results will be presented according to the output specification (see Appendix 1 Output Shells). Study biostatistician is responsible for writing the plan with necessary input from other members of the study team. A biostatistician not otherwise involved in the study together with the coordinating investigator will approve the final version.

The SAP is based on the study protocol:
Protocol ID: MedBridge Version: 19-02-20

Analysis will start once all data for the last included patient (12-month follow-up) have been obtained, the database has been cleaned and locked, and the SAP has been finalized.

2. Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADD</td>
<td>Automated drug dispensing system</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>C</td>
<td>Control group (usual care)</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic Obstructive Pulmonary Disease</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>DMP</td>
<td>Data Management Plan</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic Case Report Form</td>
</tr>
<tr>
<td>EDC</td>
<td>Electronic Data Capture system (Castor EDC in this study)</td>
</tr>
<tr>
<td>FU</td>
<td>Follow-up</td>
</tr>
<tr>
<td>HF</td>
<td>Congestive Heart Failure</td>
</tr>
<tr>
<td>ITT</td>
<td>Intention to Treat</td>
</tr>
<tr>
<td>mITT</td>
<td>Modified Intention to Treat</td>
</tr>
<tr>
<td>I1</td>
<td>Intervention 1 (medication review during hospital stay)</td>
</tr>
<tr>
<td>I2</td>
<td>Intervention 2 (medication review during hospital stay with active follow-up after discharge)</td>
</tr>
<tr>
<td>RR</td>
<td>Incidence Rate Ratio</td>
</tr>
<tr>
<td>RG</td>
<td>Region Gävleborg</td>
</tr>
<tr>
<td>RU</td>
<td>Region Uppsala</td>
</tr>
<tr>
<td>RV</td>
<td>Region Västmanland</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SD</td>
<td>Standard Deviation</td>
</tr>
<tr>
<td>SEK</td>
<td>Swedish Krona</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedures</td>
</tr>
<tr>
<td>UAS</td>
<td>Uppsala University Hospital</td>
</tr>
<tr>
<td>UCR</td>
<td>Uppsala Clinical Research center</td>
</tr>
</tbody>
</table>
3. Study Objectives and Endpoints

3.1. Objectives

3.1.1. Primary Objective

a) The first primary objective is to test the hypothesis that the incidence of unplanned hospital visits (admissions plus visits to the emergency department) among elderly patients during a one-year follow-up is lower, if they receive a comprehensive medication review with active follow-up after discharge, than if they receive usual care.

b) The second primary objective is to test the hypothesis that a comprehensive medication review with active follow-up after discharge reduces the incidence of unplanned hospital visits more than only a medication review during hospital stay compared to usual care.

3.2. Endpoints

3.2.1. Primary Endpoint

The primary endpoint is incidence of unplanned hospital visits (admissions plus visits to the emergency department) during a 12-month follow-up period. An unplanned visit is defined as a visit which has not been part of the patient’s treatment plan (scheduled visit), but results from an acute health problem.

3.2.2. Secondary Endpoints

- Separate incidences of unplanned hospital admissions and emergency department visits after 30 days, 3, 6 and 12 months
- Incidences of unplanned hospital visits after 30 days, 3 and 6 months
- Separate incidences of unplanned medication related hospital admissions and unplanned primary care physician visits after 30 days, 3, 6 and 12 months
- Time from hospital discharge to first unplanned hospital visit during 12 months
- [Costs of hospital-based care (costs of healthcare utilisation including the costs of the intervention) after 6 and 12 months]
- All-cause mortality rates after 30 days, 3, 6 and 12 months

Secondary outcomes include the primary outcome applied to the following subgroups according to baseline characteristics:

- Age: 65-74 years vs. ≥75 years
- Number of unplanned hospital visits within 12 months before admission: 0-1 vs. >1 visits
- Number of prescribed medications upon admission: <5 vs. 5-9 vs. ≥10 medications
- Using an automated drug dispensing system in the home care situation vs. no automated drug dispensing system
• Previously diagnosed diseases according to the patient’s electronic health record: congestive heart failure (HF) vs. no HF; chronic obstructive pulmonary disease (COPD) vs. no COPD; diabetes mellitus (DM) vs. no DM

4. Study design

This is a cluster-randomised, three-treatment, replicated, crossover design with study periods of 8 weeks. [4,5]

Crossover and randomisation took place at ward level within each hospital, so that one ward is one cluster. This means that each ward was allocated to one intervention (I1, I2 or control) during three consecutive periods of eight weeks. Changes over time, such as seasonal differences, and any significant changes to the cluster setting during the study’s inclusion period, such as an outbreak of multi-resistant bacteria at one of the study wards, can also influence the study outcomes. To account for any of these temporal effects, the three consecutive 8-week periods were rotated twice, and randomisation of intervention sequences was performed (see Fig. 1). Contamination risk monitoring, in terms of ward personnel covering several study wards at the same time, was performed as well. The total study duration consists of six consecutive periods of eight weeks per cluster. This means that each cluster performed each intervention for 16 active study weeks. To assure that each cluster performed each intervention twice, randomisation took place at hospital level in two blocks of three periods. This within-hospital block randomisation was chosen to spread out the different study periods more equally over the full study period, to account for period effects. Due to logistical, staffing reasons the method of block randomisation also prevents a particular intervention being concurrently performed on both wards within the same hospital. Allocation concealment was not possible during the rest of the study. However, we regard the lack of concealment as being of minor importance due to the crossover aspect of the trial (all clusters will perform each intervention twice). To minimise the possibility of selection bias within the clusters, all eligible patients were asked for informed consent to be included in the study. It was explained to the patients that they would receive the particular intervention whether or not they provided informed consent. By this measure we aimed to minimise the risk of consent bias. Any included patient that was readmitted to one of the study wards received the intervention that was being performed at that particular moment. A hypothetical randomisation chart to visualise the block randomisation is shown in Fig. 1.

![Figure 1](chart.png)
5. Definition of Analysis Populations

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dropouts</td>
<td>Patients that were eligible for the study (according to the inclusion and exclusion criteria) but did not provide informed consent and were not included in the study.</td>
</tr>
<tr>
<td>Withdrawals</td>
<td>Patients that fulfilled inclusion criteria and have signed informed consent but withdrew after inclusion (before data were collected).</td>
</tr>
<tr>
<td>Intention to treat (ITT)</td>
<td>All patients that were eligible for the study (including patients that did not provide informed consent but who were eligible). All participants will be analysed according to the intervention group (C, I1 or I2) to which the cluster (ward) was allocated upon admission (index admission). Withdrawals will be included.</td>
</tr>
<tr>
<td>Modified Intention to treat (mITT)</td>
<td>All patients that fulfilled inclusion criteria and have signed informed consent. All participants with a recorded outcome will be included in the analysis and will be analysed according to the intervention group to which the cluster was allocation upon inclusion (index admission).</td>
</tr>
</tbody>
</table>

The ITT population will only be used as a supportive analysis for the primary endpoint. The mITT population will be used in primary endpoint analyses and all other analyses.

6. Description of statistical analysis

6.1. General

All analyses will account for the cluster-randomized crossover design to ensure correct type I error rates and confidence intervals (CIs). A significance level of 0.05 (two-tailed) will be used for all statistical comparisons.

6.2. Patient and Cluster Characteristics

A table that summarizes number of patients by intervention group (C, I1 and I2) in total and by cluster, will be constructed. Number of patients in each intervention group will be presented together with number (proportion) and reason of drop-outs among intervention groups.

All endpoints will be summarized by intervention group, at both subject, period and cluster level (ward) using descriptive statistics. Patients and cluster characteristics will be presented by intervention group (C, I1 and I2) in a table, but no formal statistical hypothesis testing will be performed. Continuous variables will be summarized by number of observations (n), mean, standard deviation (SD), median, minimum (min) and maximum (max). Categorical variables will be summarized in frequency tables (presenting frequencies and proportions).
6.3. Primary analyses

The differences in the incidences of unplanned hospital visits during a 12-month follow-up period (admissions plus visits to the emergency department) between intervention groups (C, I1, I2) will be compared using log-linear models with Poisson variance function in the framework of Generalized Linear Mixed Models with adjustment for the cluster effect (ward) and period effect. Number of unplanned hospital visits within 12 months before index admission (continuous variable) will be included as a patient level covariate. Number of unplanned hospital visits before admission may be categorized (0, 1, 2, 3, 4 and >4 admissions). The number of out-of-hospital-days (log-transformed) will be used as offset. Pairwise comparisons will be performed:
I2 vs C
I2 vs I1
I1 vs C

Results will be presented as p-value, estimated rate ratio (RR) and 95% CI for comparison between groups. Tukey’s adjusted p-values and 95% CI may be presented for pairwise comparisons to prevent multiple testing problem. SAS procedure GLIMMIX will be used [6,7].

6.4. Secondary analyses

Incidences of
- Unplanned hospital admissions after 30 days, 3, 6 and 12 months
- Emergency department visits after 30 days, 3, 6 and 12 months
- Unplanned hospital visits after 30 days, 3 and 6 months
- Unplanned medication related hospital admissions after 30 days, 3, 6 and 12 months
- Unplanned primary care physician visits after 30 days, 3, 6 and 12 months

will be performed using the same statistical methods as for the primary objective (other definition of the outcome variable and offset, see section 9). All above analyses will be adjusted for number of unplanned hospital visits within 12 months before index admission.

Time to event analyses:
- Time to first unplanned visit during 12 months
- All-cause mortality after 30 days
- All-cause mortality after 3 months
- All-cause mortality after 6 months
- All-cause mortality after 12 months

will be analysed with nested frailty models including gamma distributed random effect. Period will be implemented as fixed and cluster (ward) as random effect. Kaplan Meier curves will be constructed for each outcome definition. Number of unplanned hospital visits within 12 months before index admission will be included as a patient level covariate. Results will be presented as p-value, Hazard Ratio (HR) and 95% CI for comparison between groups. Pairwise comparisons may be used. EFRON method will be used for handling of ties in failure times.[8] SAS procedure PHREG will be used.
Costs of hospital based care (cost for healthcare utilization including the cost for the intervention) after

i) 6 months

ii) 12 months

will be presented as mean (SD) and median values with interquartile range (IQR; 25th–75th percentiles) by each intervention group (C, I1, I2). Non-parametric bootstrap method [9] will be used to compare cost and to estimate confidence intervals. Costs of hospital-based care is not the part of the current assignment and will not be analysed and presented in this report.

6.5. Subgroup analyses

The differences in the incidences of unplanned hospital visits during a 12-month follow-up period (admissions plus visits to the emergency department) between intervention groups (C, I1, I2) will be analyses in following subgroups according to baseline characteristics:

- Age (65-74 vs. ≥ 75 years)
- *Number of unplanned hospital visits within 12 months before admission: (0–1 vs. >1 visits)
- Number of prescribed medications upon admission (< 5 vs. 5–9 vs. ≥ 10 medications)
- Using an automated drug dispensing system in the home care situation vs. no automated drug dispensing system
- Previously diagnosed diseases according to the patient's medical record:
  i) congestive heart failure (HF) vs. no HF
  ii) chronic obstructive pulmonary disease (COPD) vs. no COPD
  iii) diabetes mellitus (DM) vs. no DM.

We will identify possible groups that respond better or worse to the intervention. A test for interaction, using multivariable models, to evaluate for statistically significant subgroup differences will therefore be used. Interactions will be explored graphically. We will present the outcome means for the interaction between intervention group and each subgroup. Subgroup analyses will then be performed, and results will be presented as p-value, estimated rate ratio (RR) and 95% CI for comparison between treatments by each subgroup.

NOTE: *This subgroup analysis will not be adjusted for number of unplanned hospital visits within 12 months before index admission.
6.6. Overdispersion

A restriction in the use of Poisson models is that the model assumes that the variance is equal to the mean. We can therefore often observe overdispersion in such models, i.e. the actual observed variation is too large to fit the theoretical model. An indication of overdispersion is that Persons ratio (values of Gener. Chi-Square /DF) is (much) larger than 1, which may be the case in our models. Running overdispersed Poisson models will generate understated standard errors and can lead to erroneous conclusions. We will therefore take that into account by adding a multiplicative overdispersion parameter to the variance function in all our GLIMMIX models.

6.7. Handling of Missing Data

Definition of ITT population requires that dropouts are included. Primary outcome variable (number of unplanned visits) will be imputed for patients that drop out and withdrawals, about 10% of the total number of included patients. All necessary information (period, cluster and planned intervention groups) for drop-outs is available. Multiple imputation (MI) method will be used to deal with missing data in the primary outcome variable. We will use SAS function PROC MI and generate ten imputed datasets (to ensure that our effect estimates will not overlay inaccurate due to Monte Carlo variability). The results for each imputation will be combined using SAS function PROC MIANALYZE. We will perform two sensitivity analyses:

1. According to MAR (missing at random) assumption.
   We assume that missingness is conditional on study period, intervention group and cluster and then perform the sensitivity analyses.
2. According to MNAR (missing not at random) assumption
   We will use an adjust option where imputed values for observations in the intervention group (I2) are adjusted using the shift parameter. (SHIFT option adds a constant to the imputed value). In this way, the expected value of the intervention group I2 will be higher than that of the corresponding of the observed I2 values. We will investigate which shift parameter reverses the study conclusion.

Regarding sensitivity analyses: We will not be able to adjust for the number of out-of-hospital-days and the number of unplanned hospital visits within 12 months before index admission because we don’t have these variables for dropouts.

7. Determination of sample size

The proposed cluster-randomised crossover design will result in an approximately 1:1:1 ratio of study participants in I1, I2 and in the control group. In our previous study in which we compared a comprehensive medication review with usual care at two hospital wards, the reduction in hospital visits was 16% [1]. Due to the multicentre nature of the current study, as well as an expected 20% of the patients revisiting study wards and receiving one or more additional study interventions (possibly diluting the estimated difference between groups), the expected reduction in this study is approximately 10%. Based on our previous RCT and data from our pilot study, we expect an incidence of two hospital visits (per patient year) in
the control group. This means that a 10% reduction would result in Number Needed to Treat (NNT) of five to prevent one hospital visit during the 12 months follow-up, which we consider highly clinically relevant.

Power simulations were performed using the R package clusterPower version 0.5 [2,3]. The power simulations were based on a fixed effects Poisson regression with a between cluster variance of 0.5. Analyses at the cluster level was assumed, even though the subsequent analyses will be performed at the individual level. We used anticipated cluster sizes from the pilot study (i.e. varying cluster sizes), with eight clusters and six periods per cluster in total. The expected mean number of at-risk days per patient was 290 and we assumed seven hospital visits per 1000 patient-days in the control group. With these assumptions, 2310 study participants in total would be needed to show a 10% reduction of hospital visits between I2 and the control group with a power of approximately 83% (α=5%). The corresponding power for an expected 3% difference between I1 and I2 would be approximately 48%.

No compensation for withdrawals has been accounted for in the sample size estimation, since the primary analysis will be based on the mITT population.

8. **Changes in the Planned Analysis**

1. The following planned analysis is deleted because it was not feasible to define the PP-population:

   “In addition, supportive analyses will be performed using PP analyses, i.e. excluding patients and/or clusters where protocol violations have occurred, and as-treated analyses on a per-patient basis.”

   Instead, we will use the ITT population when performing supportive analyses for the primary endpoint and the mITT population for the primary and secondary analysis.

2. The following planned analysis described in study protocol section 3.9 will be changed:

   “In order to control the overall type I error, the two primary objectives will be tested in a hierarchical fashion starting with I2 versus control. If the p-value for this comparison is below 0.05, the test for I1 versus control will be performed at the 0.05 level. If the p-value for the first comparison is above 0.05, formal testing for the second comparison will not be undertaken”

   All pairwise comparisons will be performed instead. Tukey’s method will be used to prevent multiple testing problem. Both adjusted and unadjusted CI will be presented.
9. Description of Derived Variables

All-cause mortality Defined as time from inclusion until death from any cause. Status will be defined as 1=dead, 0=alive or censored.
If Avliden_datum ne . then dead=1; If Avliden_datum =. then dead=0

Death days Time to death. Censored at 365 days.
Death_days = Avliden_datum minus Indexdatum
If Death_days=. then Death_days=365

All-cause mortality after
30 days Defined as time from inclusion until death from any cause within 30 days. Status will be defined as 1=dead, 0=alive or censored.
If Death_days <31, then "1", otherwise "0"

Death days after 30 days Death days censored at 30 days
Death_days_1M= Death_days
If Death_days>30 then Death_days_1M=30

All-cause mortality after
3 months Defined as time from inclusion until death from any cause within 3 months. Status will be defined as 1=dead, 0=alive or censored.
If Death_days <91, then "1", otherwise "0"

Death days after 3 months Death days censored at 3 months
Death_days_3M= Death_days
If Death_days>90 then Death_days_3M=90

All-cause mortality after
6 months Defined as time from inclusion until death from any cause within 6 months. Status will be defined as 1=dead, 0=alive or censored.
If Death_days <181, then "1", otherwise "0"

Death days after 6 months Death days censored at 6 months
Death_days_6M= Death_days
If Death_days>180 then Death_days_6M=180

Length of stay If typ="Sjukhusvistelse" and indexvistelse=0 then
days= kontakt_slut_date- kontakt_start_date +1
If several hospital visits, summarize all “days” within the patient.

Number of days at risk 365 minus sum of Length_of_stay (by patient).
This variable will be used as offset in GLIMMIX

Unplanned hospital Admissions
Unplanned Hospital admissions and (no index)
If typ="Sjukhusvistelse" and oplanerad=1 and indexvistelse=0
then UHA_12=1
4 variables will be created, UHA_12,UHA_6,
UHA_3 and UHA_1 which corresponds to UHA after 1,3,6 and 12 months.

Emergency department visits

If typ="Akutbesök" then ED_visit_12=1
4 variables will be created, ED_visit_12, ED_visit_6, ED_visit_3 and ED_visit_1 which corresponds to number of emergency department visits after 1,3,6 and 12 months, respectively.

Unplanned medication related hospital admissions

If UHA_12=1 and MRA=1 then MRA_visit_12=1
4 variables will be created, MRA_visit_12, MRA_visit_6, MRA_visit_3 and MRA_visit_1 which corresponds to number of medication related hospital admissions after 1,3,6 and 12 months, respectively.

Unplanned primary care physician visits

If typ="Primärvårdsbesök" and kategori="Läkare/läkarstudent" then GP_visit_12=1
4 variables will be created, GP_visit_12, GP_visit_6, GP_visit_3 and GP_visit_1 which corresponds to number of primary care physician visits after 1,3,6 and 12 months, respectively.

Primary outcome

Unplanned hospital admissions plus visits to the emergency department after 12 months.

Primary_outcome=ED_visit_12=1 plus UHA_12=1

3 secondary outcome variables will be created, Secondary_outcome_6, Secondary_outcome_3 and Secondary_outcome_1 which corresponds to number of unplanned hospital visits after 1,3,6 and 12 months, respectively.

Time to first unplanned visit

If first primary outcome=1 then time_to_first_visit=kontakt_start_date minus Indexdatum (within 12 months)
Patients with no unplanned visits will be censored at 365 days.

Cost_6M

Sum of cost of hospital based care (in SEK) within 6 months

Cost_12M

Sum of cost of hospital based care (in SEK) within 12 months
10. **Description of Output**

See Appendix 1: MedBridge SAP Appendix 1 (OS)

11. **Statistical software**

SAS version 9.4 or later and R (version 3.2.2) will be used.

12. **References**


Cluster-crossover design: A method for limiting clusters level effect in community-intervention studies
June 2007 Contemporary Clinical Trials 28(3):316-23

[5] Eldridge S1, Kerry S, Torgerson DJ.
Bias in identifying and recruiting participants in cluster randomised trials: what can be done?
BMJ 2009;339:b4006

The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality
Trials. 2016 Dec 6;17(1):575

[7] Insights into Using the GLIMMIX Procedure to Model Categorical Outcomes with Random Effects
Kathleen Kiernan, SAS Institute Inc.
Paper SAS2179-2018

Hertz-Picciotto I1, Rockhill B.